Methods of treating fabry patients having renal impairment
US10251873B2 · kind B2 · utility
48Cited by
0References
21Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 30, 2018 |
| Grant date | Apr 9, 2019 |
| Priority date | — |
| Expiry date | May 30, 2038 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/48
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided are methods for treatment of Fabry disease in a patient having renal impairment and/or elevated proteinuria. Certain methods comprise administering to the patient about 100 to about 150 mg free base equivalent of migalastat or salt thereof at a frequency of once every other day. Certain methods also provide for the stabilization of renal function, reducing left ventricular mass index, reducing plasma globotriaosylsphingosine and/or increasing α-galactosidase A activity in the patient.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.